From: Adverse infusion reactions to rituximab in systemic lupus erythematosus: a retrospective analysis
Management | No. | % of total reactions | Retreated? |
---|---|---|---|
Able to resume/complete infusion | 8 | 28.6% | Y - 1 (2 further cycles with reaction) |
Had to cease infusion | 7 | 25.0% | Y - 1 (2 further cycles) |
Hospital Admission > 24 h | 3 | 10.7% | Y - 1 (1 further cycle) reaction) |
Delayed reaction | 5 | 17.9% | Y - 1 (1 further cycle) |
Unclassifieda | 4 | 14.3% | N |
Death | 1 | 3.6% | n/a |